Trinity Delta Comments on HUTCHMED FY2027 Earnings

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) – Research analysts at Trinity Delta issued their FY2027 earnings estimates for shares of HUTCHMED in a research note issued to investors on Tuesday, June 9th. Trinity Delta analyst L. Gregorek forecasts that the company will earn $0.31 per share for the year. The consensus estimate for HUTCHMED’s current full-year earnings is $0.47 per share.

HCM has been the topic of several other research reports. Bank of America lowered their price objective on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, March 10th. Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings lowered HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 1st. Finally, Morgan Stanley set a $13.60 price objective on HUTCHMED in a research report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $16.80.

HUTCHMED Trading Up 2.3%

Shares of NASDAQ:HCM opened at $10.87 on Thursday. HUTCHMED has a twelve month low of $10.40 and a twelve month high of $19.50. The company’s 50 day moving average is $13.28 and its 200 day moving average is $13.98. The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.05.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Blue Trust Inc. lifted its position in shares of HUTCHMED by 131.5% during the 4th quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock valued at $103,000 after buying an additional 4,378 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of HUTCHMED by 4.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after buying an additional 698 shares in the last quarter. Bank of America Corp DE lifted its position in shares of HUTCHMED by 17.3% during the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after buying an additional 3,035 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of HUTCHMED by 34.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after buying an additional 5,538 shares in the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in shares of HUTCHMED during the 1st quarter valued at approximately $365,000. Hedge funds and other institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.